Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0AIOW)

Drug Name
5-methyl nicotinic acid Drug Info
Synonyms
5-Methylnicotinic acid; 3222-49-9; 5-methylpyridine-3-carboxylic acid; 5-Methyl-nicotinic acid; 5-methyl nicotinic acid; CHEMBL247132; DJDHHXDFKSLEQY-UHFFFAOYSA-N; MFCD00829036; 3-Pyridinecarboxylic acid, 5-methyl-; 5-METHYL-3-PYRIDINECARBOXYLIC ACID; 5-Methylnicotinic acid, 97%; 5-methyinicotinic acid; PubChem11961; ACMC-1AFVP; 5-methyl nicotinic aicd; EC 608-720-2; AC1L5U3L; Nicotinic acid, 5-methyl-; AC1Q5UC0; NCIOpen2_001043; 5-METHYLNICOTIC ACID; KSC222G7T; SCHEMBL185789; GTPL1592; Jsp005966; CTK1C2379; DTXSID60292444
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
256208
CAS Number
CAS 3222-49-9
TTD Drug ID
DM0AIOW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Nicotinic acid receptor (HCAR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin B3 DMQVRZH Chronic renal failure GB61.Z Approved [3]
ARI-3037MO DM9LNXS Cardiovascular disease BA00-BE2Z Phase 2 [4]
SCH-900271 DMBJY1Z Ischemic stroke 8B11.5Z Phase 2 [5]
GSK-256073 DMMAIY2 Hyperlipidaemia 5C80 Phase 2 [6]
MK-1903 DMVJB09 Arteriosclerosis BD40 Phase 2 [7]
MK-0354 DMWFTRJ N. A. N. A. Phase 2 [8]
NIA-114 DM3ADQW Plaque psoriasis EA90.0 Clinical trial [9]
INCB19602 DMRHZBD Type-2 diabetes 5A11 Discontinued in Phase 2 [10]
cinnamic acid DM340FH Discovery agent N.A. Investigative [11]
5-Benzyl-1H-pyrazole-3-carboxylic acid DMJVGUZ Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nicotinic acid receptor (HCAR2) TTWNV8U HCAR2_HUMAN Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1592).
2 Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74.
3 Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8.
6 GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Nov;15(11):1013-21.
7 Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012 Aug 22;4(148):148ra115.
8 GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 DOI: 10.1038/scibx.2010.313
11 Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). J Lipid Res. 2009 May;50(5):908-14.
12 Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.